RxDoctor Payments Data

Russell Powell, MD

Neurology · Ventura, CANPI 1194015305

Payments from drug & device makers

$5,522in general payments, 2019–2025

Across 279 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$1K
  • Livanova USA, Inc.$935
  • Pfizer$508
  • Biogen$327
  • EMD Serono, Inc.$275
  • plus $963 from 18 others

What the payments were for

  • Speaking & faculty fees$140%
  • Travel & lodging$3847%
  • Food & beverage$5,11193%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,522 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$11,970
Medicare patients
69
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin13$124,126
EpidiolexCannabidiol (Cbd)25$96,129
Nurtec OdtRimegepant Sulfate72$88,251
BriviactBrivaracetam48$84,096
QuliptaAtogepant29$64,550
VimpatLacosamide34$51,636
Aimovig AutoinjectorErenumab-Aooe40$45,185
FycompaPerampanel22$26,098
Levetiracetam419$24,323
Tetrabenazine12$22,339
Emgality PenGalcanezumab-Gnlm29$19,539
Lacosamide219$18,506
NayzilamMidazolam28$17,263
Clobazam79$12,898
Memantine Hcl248$7,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$1,239$152,994110 claims
EMD Serono, Inc.Rebif$275$124,12613 claims
PfizerNurtec Odt$508$88,25172 claims
AbbVieQulipta$1,274$64,55029 claims
Eisai Inc.Fycompa$79$26,09822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →